BALTIMORE, Sept. 12, 2011 /PRNewswire/ — CSA Medical, Inc. (www.CSAmedical.com), the leading developer of novel Spray Cryotherapy devices that flash freeze and treat diseased tissue inside the body, today announced the appointment of Wendelin Maners to the newly created position of Vice President, Emerging Therapies. In this role Maners will be responsible for the development of new therapeutic applications for the company’s Spray Cryotherapy technology.
"Wendelin has an impressive track record of working closely with executive teams and applying a thoughtful, analytical and collaborative approach to building new markets and solidifying current platforms," said Bill Floyd, CEO and president of CSA Medical. "Throughout her career she has also executed over $3 billion in transactions that provided product and therapy diversification to maximize shareholder value. We are thrilled to have her join our team."
Maners brings to CSA Medical more than 18 years of global medical device experience focused on acquisition, licensing and marketing emerging technologies. Most recently she served as Vice President, Strategy and Business Development at Boston Scientific Corporation where she developed and executed acquisition and investment strategies in the Neuromodulation and Electrophysiology markets, as well as new markets for the company. During her tenure at Boston Scientific, Maners’ focus also included entering the implantable microelectronics space with the acquisition of Advanced Bionics and leading the due diligence and negotiations for the acquisition of CryoCor, an endocardial cryo ablation technology for atrial fibrillation. From 2000-2003, Ms. Maners worked as an investment banker with Barrington Associates (Wells Fargo Securities). Previously she held marketing positions focused on entering new markets with Boston Scientific’s urology and interventional neuroradiology divisions. Maners holds a bachelor of science degree in Business Administration from the University of Southern CaliforniaMarshall School of Business.
"I believe that CSA Medical’s Spray Cryotherapy device has tremendous potential to treat multiple disease states, drastically improve patient outcomes and reduce the cost of healthcare," said Maners. "I look forward to working with my colleagues to realize the fullest potential for this innovative technology."
About CSA Medical
CSA Medical, Inc. develops and manufactures a proprietary therapeutic interventional platform, the Spray Cryotherapy System, comprised of a device, specialty catheters and agent that allows delivery of therapeutic doses of a cryogen to flash freeze and destroy diseased tissue inside the body. The Company is the first to harness the power of extreme cold (-196 C) liquid nitrogen therapeutic energy delivery inside the body. To learn more, please visit www.CSAmedical.com.
SOURCE CSA Medical, Inc.